Rival For Opdivo As Keytruda Launches For NSCLC In Japan At Same Daily Price
Executive Summary
Opdivo has a new rival in the lung cancer setting in Japan following the reimbursement and launch of Keytruda at the same daily price.
You may also be interested in...
Opdivo, Keytruda Hit Again As Japan Revises Prices
Immuno-oncology drugs Opdivo and Keytruda will have their prices cut in the next regular Japanese price revision in April, while some other novel and big-selling products will also feel the heat under a revised framework.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.